menu
    • menu
    [{"orgOrder":0,"company":"Wisconsin Medical Cyclotron & Radiopharmacy","sponsor":"Cornerstone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wisconsin Medical Cyclotron & Radiopharmacy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wisconsin Medical Cyclotron & Radiopharmacy \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"7","companyTruncated":"Wisconsin Medical Cyclotron & Radiopharmacy \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"Wisconsin Medical Cyclotron & Radiopharmacy","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wisconsin Medical Cyclotron & Radiopharmacy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wisconsin Medical Cyclotron & Radiopharmacy \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"4","companyTruncated":"Wisconsin Medical Cyclotron & Radiopharmacy \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"Wisconsin Medical Cyclotron & Radiopharmacy","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Wisconsin Medical Cyclotron & Radiopharmacy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wisconsin Medical Cyclotron & Radiopharmacy \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"4","companyTruncated":"Wisconsin Medical Cyclotron & Radiopharmacy \/ Wisconsin Medical Cyclotron & Radiopharmacy"}]

    Find Clinical Drug Pipeline Developments & Deals by Wisconsin Medical Cyclotron & Radiopharmacy

    Menu

    Wisconsin Medical Cyclotron & Radiopharmacy

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Wisconsin Medical Cyclotron & Radiopharmacy

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Wisconsin Medical Cyclotron & Radiopharmacy

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adenosine Analog

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : Adial Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnov...

                            Details : Under the agreement, Dr. Auchampach and his team will test Purnovate’s adenosine compounds in preclinical models with the goal of further validating the potential of Purnovate’s compounds as a treatment for diabetes and NASH.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 19, 2022

                            Lead Product(s) : Adenosine Analog

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Adial Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Wisconsin Medical Cyclotron & Radiopharmacy

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Wisconsin Medical Cyclotron & Radiopharmacy

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Devimistat,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Cornerstone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimist...

                            Details : CPI-613® (devimistat) is a first-in-class clinical lead compound of Cornerstone, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 08, 2022

                            Lead Product(s) : Devimistat,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Cornerstone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Wisconsin Medical Cyclotron & Radiopharmacy

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Wisconsin Medical Cyclotron & Radiopharmacy

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : BetterLife Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BetterLife Enters Research Agreement with Medical College Wisconsin for TD-0148A Neurological Receptor Studies

                            Details : As part of the research, Dr. McCorvy’s team will work with BetterLife to delineate TD-0148A’s signaling profile against various G protein coupled receptor (“GPCR”) relevant in neuro-psychiatry.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 09, 2021

                            Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : BetterLife Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth